Clinical Trial Detail

NCT ID NCT03324373
Title Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Yousef Zakharia
Indications

renal cell carcinoma

Therapies

Everolimus + Lenvatinib

Age Groups: senior adult

No variant requirements are available.